Home » Newsletters » BioWorld Asia

BioWorld Asia

Nov. 4, 1998

View Archived Issues

TAB Faces Major-Discount Financing, Potential Insolvency

Cortecs Phase III Results Positive For Oral Calcitonin

Finland Scientists Exploring New Angiogenesis Approach

Pharmos Marijuana Analogue Can Benefit Brain Injuries

Biotechs Poor Public Image, Politics Are Hurdles In Europe

Formal Ethics Statement Affirms Industrys Primary Values, Goals

EuropaBio Meeting Cheers Industrys Progress, Future

Trinity Biotech Off-Loads Disputed Pregnancy Test

Biovectors Influenza Vaccine Shows Positive Phase I Results

Flamel Reports Revenue Rise; Plans Launch Of First Product

Glaxo Asking For FDA Approval To Market Biotas Flu Drug

GlycoDesign Aims To Uncloak Bacterias Defense Mechanisms

Peptide Therapeutics Starts Phase I Of Diarrhea Drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...